key: cord-0747921-jozf9n58
authors: Banerji, Aleena; Wolfson, Anna R.; Robinson, Lacey B.; McMahon, Aubree E.; Cogan, Amelia S.; Saff, Rebecca R.; Blumenthal, Kimberly G.
title: COVID‐19 vaccines tolerated in patients with paclitaxel and docetaxel allergy
date: 2021-11-25
journal: Allergy
DOI: 10.1111/all.15178
sha: a8191564577e2b8672550dae8cc64f4e88b3b6e3
doc_id: 747921
cord_uid: jozf9n58

After initial reports of anaphylaxis to the messenger RNA (mRNA) COVID-19 vaccines, the Centers for Disease Control and Prevention (CDC) put forth guidance stating that patients with a history of anaphylaxis to vaccine components like polyethylene glycol (PEG) should not receive the mRNA COVID-19 vaccines.1 To address this clinical challenge and decrease vaccine hesitancy, we published an approach to guide COVID-19 vaccination in high-risk allergy individuals.2-4 While the etiology of anaphylaxis to mRNA COVID-19 vaccines remains unclear, PEG continues to be an important focus.5,6 Paclitaxel contains polyoxyl-35 castor oil --a PEG derivative and structurally similar to the excipient in Pfizer-BioNTech and Moderna COVID-19 vaccines-- and docetaxel contains polysorbate 80 --the excipient in Janssen COVID-19 vaccine. Given this, we sought to assess the utility of pre-vaccine excipient skin testing (ST), risk stratification and COVID-19 vaccine tolerability in oncology patients with a history of paclitaxel or docetaxel hypersensitivity reaction (HSR).

To the Editor, After initial reports of anaphylaxis to the messenger RNA We included consecutive paclitaxel or docetaxel HSR patients referred to Mass General Brigham allergy/immunology for evaluation prior to COVID-19 vaccination. Evaluation included clinical risk assessment and excipient ST as previously described. 2, 4 Clinical details were obtained by electronic health record (EHR) review. COVID-19 vaccine tolerance was determined by an allergy/immunology physician (AB) using EHR review, phone call, and/or e-mail. This study was approved by the Massachusetts General Brigham Institutional Review Board and deemed minimal risk.

Between December 30, 2020, and April 2, 2021, 21 patients with paclitaxel (n = 17) or docetaxel (n = 4) HSR were referred (Table 1 ). Most were female (n = 20, 95%) and white (n = 20, 95%).

Approximately half of HSRs occurred in the past 4 years (n = 11, 52%), and 14 (67%) HSRs were severe grade 3. 7 Twenty patients (95%) had negative excipient ST. One paclitaxel HSR patient had positive ST (methyl-prednisolone acetate PEG3350, 0.4 mg/ml intradermal) and tolerated the Janssen COVID-19 vaccine ( Table 2 ). All patients com- This study was limited by its small sample from a single institution and retrospective study design. Additionally, the study included patients with a history of hypersensitivity to drugs (i.e., paclitaxel) that do not contain the specific form of PEG contained in the vaccines, which is a PEGylated form of PEG forming PEGylated lipids. It has been frequently reported that hypersensitivity to drugs containing PEG (in its native form) or its derivatives (and not containing the PEGylated form of PEG) is not a contraindication for receiving the COVID-19 mRNA vaccines. 8 The role of excipient ST prior to COVID-19 vaccination appears limited. 8, 9 Patients in our study largely tolerated COVID-19 vaccination despite paclitaxel or docetaxel HSR, and there is no identified role to date for the use of skin testing to PEG/polysorbate 80 prior to COVID-19 vaccination in these patients. 8 Positive to methyl-prednisolone acetate intradermal 0.4 mg/ml.

Information about COVID-19 Vaccines for People with Allergies. Center for Disease Control and Prevention

mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach

COVID-19 vaccination in patients with reported allergic reactions: updated evidence and suggested approach

First dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing

Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine

Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system

Incidence and severity of anaphylactoid reactions to colloid volume substitutes

The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach

Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in PEG allergic patients